Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095030 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,752
- Enrollment target
NCT00095030: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00095030 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,752 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (127% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00095030, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,752 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.
Interventions
- DRUG muraglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,752 participants |
| Start Date | 2004-02 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
What the finished NCT00095030 record still lists
NCT00095030 is an interventional study that assigns participants to a tested intervention. Its 1,752 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (127% higher).
The record links to 0 conditions, and to 1 intervention - of which muraglitazar is the first listed.
NCT00095030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00095030 about?
NCT00095030 is a clinical study titled "Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone". The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.
What is the current status of trial NCT00095030?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,752 participants. The study started on 2004-02. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00095030?
The interventions under investigation include: muraglitazar (DRUG).
Who is sponsoring clinical trial NCT00095030?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00095030's enrollment target sits among peer trials
1,752 129th of 2000 higher than 1,872 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07062172 · 1,753 participants · NA
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT06954337 · 1,750 participants · NA
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
- NCT07183527 · 1,750 participants · NA
Hybrid Type I Effectiveness-implementation Cluster Randomized Controlled Trial of CARES
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia